Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Combined Tests Provide Better Asthma Diagnosis

By LabMedica International staff writers
Posted on 10 Oct 2013
Fraction of exhaled nitric oxide (FENO) and blood eosinophil-count values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients.

Measurement of the concentration of exhaled nitric oxide is today a routine clinical method for determining the degree of steroid-sensitive inflammation in the airways in asthma and for many years, a count of eosinophil granulocytes in the blood has also been used to support a diagnosis of asthma.

Scientists at Uppsala University (Sweden) measured FENO and eosinophil values in 12,408 subjects aged 6 to 80 years from 2007 to 2008 and from 2009 to 2010. Current wheeze and asthma diagnosis, as well as asthma attacks and asthma-related emergency department (ED) visits within the last 12 months, were assessed by means of questionnaires.

The FENO values were measured with the NIOX MINO electrochemical analyzer (Aerocrine AB; Solna, Sweden) at an expiratory flow rate of 50 mL/second. Blood differential counts were performed by using the automated HmX hematology analyzer (Beckman Coulter; Fullerton, CA, USA). The following cutoffs for eosinophil values were used: less than 300 cells/mm3 to define normal values; 300 cells/mm3 or greater but less than 500 cells/mm3 for intermediate values and 500 cells/mm3 or greater for high values, as this is the limit for defining eosinophilia.

The scientists were able to determine that the association between FENO and blood eosinophils was very weak. Instead, they observed that simultaneously elevated levels of the two markers, in a synergistic way, but independently of each other, increased the likelihood of individuals reporting, for example, asthma symptoms or asthma attacks in the last year. The results supported their hypothesis that the two markers represent two different inflammation processes.

Kjell Alving, PhD, a professor at the Department of Children's and Women's Health, Uppsala University, and a senior author of the study said, “We therefore propose that both of these measurements be carried out in combination in order to better understand the inflammation in asthma patients. They thus constitute a better platform for selecting the proper treatment for these patients.” The study was published in the October 2013 issue of the Journal of Allergy and Clinical Immunology.

Related Links:
Uppsala University
Aerocrine AB
Beckman Coulter



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.